- Home
- RVTY vs ICLR Comparison
RVTY vs ICLR Comparison
Compare RVTY & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVTY | ICLR |
|---|---|---|
| Founded | 1937 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 11.5B |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | RVTY | ICLR |
|---|---|---|
| Price | $95.74 | $95.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 13 |
| Target Price | $113.00 | ★ $202.31 |
| AVG Volume (30 Days) | 1.6M | ★ 2.9M |
| Earning Date | 02-02-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 2.07 | ★ 7.47 |
| Revenue | $2,856,051,000.00 | ★ $8,102,602,000.00 |
| Revenue This Year | $6.06 | N/A |
| Revenue Next Year | $5.15 | $0.22 |
| P/E Ratio | $46.68 | ★ $12.44 |
| Revenue Growth | ★ 3.67 | N/A |
| 52 Week Low | $81.36 | $66.57 |
| 52 Week High | $120.39 | $211.00 |
Technical Indicators
Market Signals| Indicator | RVTY | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 38.74 | 18.36 |
| Support Level | $93.70 | $66.57 |
| Resistance Level | $106.55 | $155.00 |
| Average True Range (ATR) | 4.33 | 10.11 |
| MACD | -1.62 | -9.60 |
| Stochastic Oscillator | 15.05 | 15.95 |
Price Performance
Historical ComparisonAbout RVTY Revvity Inc.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.